|By Marketwired .||
|July 31, 2014 06:00 AM EDT||
FOSTER CITY, CA -- (Marketwired) -- 07/31/14 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the second quarter 2014 on Monday, August 11, 2014. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
(Replay available from August 11, 2014 at 8:30 pm ET until 11:59 pm ET on August 18, 2014)
The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone's website at www.sciclone.com. The information provided on the teleconference is accurate only at the time of the conference call, and SciClone will take no responsibility for providing updated information except as required by law.
SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets, including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Through its promotion business with pharmaceutical partners, SciClone markets multiple branded products in China which are therapeutically differentiated. The Company has successfully in-licensed products with the potential to become future market leaders and to drive the Company's long-term growth. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.
This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.
"Matrix is an ambitious open standard and implementation that's set up to break down the fragmentation problems that exist in IP messaging and VoIP communication," explained John Woolf, Technical Evangelist at Matrix, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 25, 2014 04:45 AM EST Reads: 1,864
Dec. 25, 2014 04:00 AM EST Reads: 1,693
Dec. 25, 2014 04:00 AM EST Reads: 1,955
Dec. 25, 2014 04:00 AM EST Reads: 1,926
Dec. 25, 2014 03:00 AM EST Reads: 2,238
Dec. 25, 2014 03:00 AM EST Reads: 1,730
Dec. 25, 2014 02:30 AM EST Reads: 2,084
Dec. 25, 2014 02:00 AM EST Reads: 2,608
Dec. 25, 2014 02:00 AM EST Reads: 1,633
Dec. 25, 2014 02:00 AM EST Reads: 2,142
Dec. 25, 2014 01:00 AM EST Reads: 1,658
Dec. 25, 2014 01:00 AM EST Reads: 1,932
Dec. 25, 2014 01:00 AM EST Reads: 1,801
Dec. 25, 2014 01:00 AM EST Reads: 2,035
Dec. 25, 2014 12:00 AM EST Reads: 2,349